:
Interleukin-15 (IL-15) was identified in 1994 as a T-cell growth factor with the capability to mimic the
functions of IL-2. IL-15 engages with the IL-15Rα subunit expressed on the surface of antigen-presenting cells
(APCs) and, through a trans-presentation mechanism, activates the IL-2/IL-15Rβγ complex receptor on the surface
of natural killer (NK) cells and CD8+ T cells. This interaction initiates a cascade of downstream signaling
pathways, playing a pivotal role in the activation, proliferation, and anti-apoptotic processes in NK cells, CD8+ T
cells, and B cells. It provides a substantial theoretical foundation and potential therapeutic targets for tumor immunotherapy.
Whether through active or passive immunotherapeutic strategies, IL-15 has emerged as a critical
molecule for stimulating anti-tumor cell proliferation.